Drug profile · INN
neostigmine methylsulfate
NEOSTIGMINE METHYLSULFATE
neostigmine methylsulfate (NEOSTIGMINE METHYLSULFATE) is a acetylcholinesterase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — neostigmine methylsulfate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
neostigmine methylsulfate (NEOSTIGMINE METHYLSULFATE) is a acetylcholinesterase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Acetylcholinesterase inhibitor
Primary target: Acetylcholinesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is neostigmine methylsulfate?
neostigmine methylsulfate (NEOSTIGMINE METHYLSULFATE) is a acetylcholinesterase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for neostigmine methylsulfate?
NEOSTIGMINE METHYLSULFATE is a marketed brand name for neostigmine methylsulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of neostigmine methylsulfate?
neostigmine methylsulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.